Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03436771 · ClinicalTrials.gov registry record
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
A clinical trial, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- Terminated
- Registry status
- 4
- Enrollment target
NCT03436771: Clinical Trial study, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
NCT03436771 is a clinical trial that was terminated before completion, run by Juno Therapeutics, a Subsidiary of Celgene. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03436771 was terminated before completion, sponsored by Juno Therapeutics, a Subsidiary of Celgene.
- TERMINATED
- Registry status
- 4 participants
- Enrollment target
Study Summary
This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.
Interventions
- GENETIC JCAR017
- GENETIC JCARH125
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-02-19 |
| Est. Completion | 2018-07-20 |
Why NCT03436771 stopped before completion
NCT03436771 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which JCAR017 is the first listed.
NCT03436771 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03436771 about?
NCT03436771 is a clinical study titled "Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product". This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, pres...
What is the current status of trial NCT03436771?
This trial is currently terminated. The enrollment target is 4 participants. The study started on 2018-02-19. Estimated completion is 2018-07-20.
What interventions are being tested in trial NCT03436771?
The interventions under investigation include: JCAR017 (GENETIC), JCARH125 (GENETIC).
Who is sponsoring clinical trial NCT03436771?
This trial is sponsored by Juno Therapeutics, a Subsidiary of Celgene, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI